RESEARCH TRIANGLE PARK, N.C. - BioCryst Pharmaceuticals , Inc. (NASDAQ:BCRX), currently trading at $8.05 with a market capitalization of $1.67 billion, provided a financial outlook for 2025, forecasting that net revenue for ORLADEYO (berotralstat) will be between $515 million and $535 million. The company also anticipates total revenue, including RAPIVAB (peramivir injection), to range from $540 million to $560 million for the year. According to InvestingPro data, the company has demonstrated strong revenue growth of nearly 30% over the last twelve months.
In a recent statement, BioCryst revealed preliminary unaudited figures for the fourth quarter and full year of 2024, with ORLADEYO net revenue for the year reaching $437 million, marking a 34 percent year-over-year increase. The company's total revenue for 2024 was at approximately $450 million, a 36 percent increase from the previous year.
BioCryst's Chief Commercial Officer, Charlie Gayer, highlighted the growth in ORLADEYO revenue and the drug's acceptance in over 30 countries. The company is preparing to submit a new drug application for ORLADEYO granules for children up to age 12, addressing a significant unmet need.
The company's operating expenses for 2025 are projected to be between $485 million and $495 million. Excluding an estimated $60 million in stock-based compensation, the operating expenses are forecasted to be between $425 million and $435 million.
BioCryst achieved operating profit in 2024, excluding stock-based compensation, and anticipates approaching quarterly earnings per share (EPS) profitability and positive cash flow in the second half of 2025. The company expects an annual compound annual growth rate (CAGR) for revenue of around 20 percent over the next three years, compared to a projected annual operating expense CAGR of about five percent. InvestingPro analysis shows the company maintains a healthy current ratio of 2.78, indicating strong liquidity position. Subscribers to InvestingPro can access detailed financial health metrics and 6 additional ProTips for deeper insights into BioCryst's performance.
The company's pipeline is advancing, with patient studies for Netherton syndrome (BCX17725) and diabetic macular edema (avoralstat) planned for 2025.
The financial guidance and revenue projections are based on a press release statement from BioCryst Pharmaceuticals, Inc. and reflect the company's performance and expectations, but actual results may vary. Analyst consensus from InvestingPro shows price targets ranging from $8 to $30, suggesting potential upside. For comprehensive analysis including Fair Value estimates and detailed financial metrics, investors can access the full Pro Research Report, available exclusively to InvestingPro subscribers.
In other recent news, BioCryst Pharmaceuticals has reported a significant 36% year-over-year increase in its third-quarter revenue, primarily driven by its ORLADEYO product, with total revenue reaching $117.1 million. The company has also revised its 2024 revenue guidance to between $430 and $435 million and forecasts reaching $1 billion in annual revenue by 2029. In addition to these earnings and revenue results, BioCryst has made progress in its clinical trials, with BCX17725 for Netherton syndrome recently entering the clinical stage and plans to submit regulatory filings for an oral prophylactic therapy for children with hereditary angioedema by 2025.
Another major development is the adjustment in the wholesale acquisition cost of ORLADEYO, which now stands at $44,484.33 per pack, an increase from the previous cost of $42,366.03. This change was confirmed through a filing with the Securities and Exchange Commission. BioCryst maintains a healthy gross profit margin of 52.14%, according to analysis by InvestingPro, which suggests strong pricing power in its market.
Lastly, the company aims for quarterly cash flow positivity by late 2024 and expects full-year profitability in 2026. BioCryst also plans to add approximately 200 new patients annually, outpacing last year's rate by 14-15%. However, a slight slowdown in quarterly sales growth for ORLADEYO is expected in Q4 2024 and 2025. These are some of the recent developments concerning BioCryst Pharmaceuticals.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.